Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Knoll claims two series of compounds for CNS disorders

March 14, 1997

Akzo Nobel reveals new dopamine antagonists

March 14, 1997

NMDA antagonists claimed by Novartis

March 14, 1997

Antiparkinson Rx from Sumitomo in pivotal European trials

March 13, 1997

Somatostatin receptor antagonists prepared by Novartis

March 13, 1997

First approval for naratriptan

March 12, 1997

Pfizer initiates clinical trial in panic disorder

March 12, 1997

Bayer claims potassium channel modulators

March 12, 1997

Cytogen seeks Canadian approval for Quadramet

March 11, 1997

Painless local dermal anesthesia now available

March 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...